Thomas Catinazzo Sells 6,802 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 6,802 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $6.06, for a total transaction of $41,220.12. Following the completion of the sale, the chief financial officer now owns 306,391 shares in the company, valued at approximately $1,856,729.46. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $5.64 on Friday. Relay Therapeutics, Inc. has a 1 year low of $5.60 and a 1 year high of $12.14. The stock has a 50-day moving average price of $6.90 and a 200 day moving average price of $7.02.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the business earned ($0.81) earnings per share. On average, equities analysts forecast that Relay Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

RLAY has been the topic of a number of research reports. Oppenheimer downgraded shares of Relay Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 10th. Bank of America upped their price target on Relay Therapeutics from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Stifel Nicolaus reiterated a “buy” rating and set a $28.00 price objective on shares of Relay Therapeutics in a research report on Monday, September 16th. Barclays lifted their target price on Relay Therapeutics from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Relay Therapeutics in a report on Monday, October 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.11.

Hedge Funds Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RLAY. American International Group Inc. boosted its position in Relay Therapeutics by 4.0% during the first quarter. American International Group Inc. now owns 46,686 shares of the company’s stock valued at $387,000 after purchasing an additional 1,810 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Relay Therapeutics by 6.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company’s stock valued at $292,000 after buying an additional 2,547 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Relay Therapeutics by 14.9% in the 1st quarter. ProShare Advisors LLC now owns 26,214 shares of the company’s stock valued at $218,000 after buying an additional 3,394 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Relay Therapeutics by 7.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 54,917 shares of the company’s stock worth $456,000 after buying an additional 3,684 shares during the last quarter. Finally, EverSource Wealth Advisors LLC bought a new position in Relay Therapeutics during the second quarter valued at approximately $37,000. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.